Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access


Bupropion XL use in comorbidity of depression and restless leg syndrome: a case report

Onur Durmaz, Mehmet Alpay Ateş.

Restless leg syndrome (RLS) is a sensorimotor disorder with symptoms including uncomfortable subjective sensations in the legs and the urge to move them. This common disorder affects 10% of the population and may reduce quality of life. The pathophysiology of RLS is not well understood but dysfunction of dopaminergic pathways is the most prominent theory. Antidepressants, especially SSRIs, can aggravate the symptoms of RLS. Here we present a 42 year old woman diagnosed with major depressive disorder and comorbid RLS and who had been treated with paroxetine 20 mg/day for 2 months who benefited from switching to bupropion treatment. In this case the RLS symptoms had existed for approximately 3 years but were milder before paroxetine treatment. The patient met the diagnostic criteria for RLS. We used the International Restless Legs Scale (IRLS) and Montgomery-Asberg Depression Rating Scale (MADRS) to measure the patient’s symptom severity. The severity of her depressive symptoms was similar to baseline despite the two month paroxetine treatment. Due to symptoms of RLS and her ongoing depressive complaints, we decided to switch from paroxetine to bupropion. With 150 mg/day bupropion XL treatment, her RLS symptoms improved substantially at a one month follow-up while her depression severity was not changed significantly. Due to inadequate response for depression, bupropion XL was titrated to 300 mg/day. Her depressive symptoms improved significantly at a further one month follow-up. Comorbidity of RLS and depression was found to be as a frequent occurence reported in the literature. We concluded that bupropion, as a selective noradrenergic-dopaminergic reuptake inhibitor can be a good alternative to the SSRIs for patients, who suffer from both depression and RLS.

Key words: restless legs, depression, bupropion

Share this Article

Journal of Interdisciplinary Histopathology


ScopeMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.
Scopemed Buttons